NCT02235233View on ClinicalTrials.gov

Effect of Non-Alcoholic Steatohepatitis (NASH) on the Pharmacokinetics of 99mTechnetium-Mebrofenin

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

July 31, 2016

Study Completion Date

July 31, 2016

Conditions
Non-alcoholic Steatohepatitis
Interventions
DRUG

Technetium Tc 99M Mebrofenin

Each subject will be injected with \~2.5 mCi of Technetium Tc 99M Mebrofenin

Trial Locations (1)

27514

UNC Hospitals, Chapel Hill

All Listed Sponsors
collaborator

National Institute of General Medical Sciences (NIGMS)

NIH

lead

University of North Carolina, Chapel Hill

OTHER

NCT02235233 - Effect of Non-Alcoholic Steatohepatitis (NASH) on the Pharmacokinetics of 99mTechnetium-Mebrofenin | Biotech Hunter | Biotech Hunter